Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ATPase family, AAA domain containing 5 | Starlite/ChEMBL | No references |
Homo sapiens | survival of motor neuron 2, centromeric | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus multilocularis | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Echinococcus granulosus | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Brugia malayi | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Echinococcus multilocularis | atpase aaa+ type core atpase aaa type core | Get druggable targets OG5_139225 | All targets in OG5_139225 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | Eukaryotic translation initiation factor 4E-1 | 0.056 | 0.5447 | 1 |
Brugia malayi | hypothetical protein | 0.0286 | 0.2468 | 0.3776 |
Trypanosoma brucei | Eukaryotic translation initiation factor 4E-1 | 0.056 | 0.5447 | 1 |
Loa Loa (eye worm) | TKL/RAF/RAF protein kinase | 0.0388 | 0.3579 | 0.523 |
Leishmania major | eukaryotic translation initiation factor-like protein | 0.056 | 0.5447 | 1 |
Brugia malayi | Eukaryotic translation initiation factor 4E type 3, putative | 0.0067 | 0.0092 | 0.0141 |
Giardia lamblia | Hypothetical protein | 0.0067 | 0.0092 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0067 | 0.0092 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0067 | 0.0092 | 0.5 |
Onchocerca volvulus | Putative eukaryotic translation initiation factor 4e | 0.0067 | 0.0092 | 1 |
Schistosoma mansoni | eukaryotic translation initiation factor 4e | 0.056 | 0.5447 | 0.8016 |
Trichomonas vaginalis | eukaryotic translation initiation factor 4E, putative | 0.056 | 0.5447 | 1 |
Leishmania major | eukaryotic translation initiation factor eIF-4E, putative | 0.056 | 0.5447 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0684 | 0.6795 | 1 |
Echinococcus granulosus | eukaryotic translation initiation factor 4E | 0.056 | 0.5447 | 0.7988 |
Brugia malayi | translation initiation factor 4E | 0.056 | 0.5447 | 0.8333 |
Leishmania major | eukaryotic translation initiation factor-like | 0.056 | 0.5447 | 1 |
Brugia malayi | Raf kinase | 0.066 | 0.6536 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0286 | 0.2468 | 0.3564 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0286 | 0.2468 | 0.3544 |
Giardia lamblia | Translation elongation factor | 0.0067 | 0.0092 | 0.5 |
Echinococcus granulosus | raf serine:threonine protein kinase | 0.0684 | 0.6795 | 1 |
Entamoeba histolytica | eukaryotic translation initiation factor 4E, putative | 0.056 | 0.5447 | 1 |
Plasmodium falciparum | eukaryotic translation initiation factor 4E | 0.0067 | 0.0092 | 0.5 |
Trichomonas vaginalis | eukaryotic translation initiation factor 4E, putative | 0.056 | 0.5447 | 1 |
Echinococcus multilocularis | raf serine:threonine protein kinase | 0.0684 | 0.6795 | 0.5745 |
Plasmodium vivax | translation initiation factor 4E, putative | 0.0067 | 0.0092 | 0.5 |
Brugia malayi | eukaryotic translation initiation factor 4E-1 | 0.0067 | 0.0092 | 0.0141 |
Entamoeba histolytica | eukaryotic translation initiation factor 4E, putative | 0.056 | 0.5447 | 1 |
Plasmodium falciparum | eukaryotic translation initiation factor 4E, putative | 0.0067 | 0.0092 | 0.5 |
Loa Loa (eye worm) | raf kinase | 0.0681 | 0.6759 | 1 |
Trichomonas vaginalis | eukaryotic translation initiation factor 4E, putative | 0.056 | 0.5447 | 1 |
Trypanosoma cruzi | Eukaryotic translation initiation factor 4E-1 | 0.056 | 0.5447 | 1 |
Trichomonas vaginalis | eukaryotic translation initiation factor 4E, putative | 0.056 | 0.5447 | 1 |
Echinococcus multilocularis | eukaryotic translation initiation factor 4E | 0.056 | 0.5447 | 0.3955 |
Giardia lamblia | hypothetical protein | 0.0067 | 0.0092 | 0.5 |
Toxoplasma gondii | eukaryotic initiation factor-4E, putative | 0.056 | 0.5447 | 1 |
Loa Loa (eye worm) | translation initiation factor 4E | 0.056 | 0.5447 | 0.8032 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 11.2202 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 16.3601 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.